Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
保羅·拉維歐萊特將與羅伯特·W·達根一起擔任聯合主席，添加了40年醫療技術開發、運營和領導經驗。
MIAMI--(BUSINESS WIRE)--Aug. 12, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director.
邁阿密--(BUSINESS WIRE)--2024年8月12日--Pulse Biosciences，Inc.（納斯達克: PLSE）（以下簡稱「公司」或「Pulse Biosciences」），一家利用其新穎專利的納秒脈衝場消融（nsPFA）技術的公司，今天宣佈任命保羅·A·拉維歐萊特加入董事會。拉維歐萊特先生被任命爲董事會聯合主席，與聯合主席羅伯特·W·達根一起擔任獨立董事。
"We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical technology space for decades," stated Pulse Biosciences' Co-Chairman Robert W. Duggan. "He adds a wealth of relevant expertise to our Board based on his experience successfully scaling some of the largest global cardiology franchises through driving innovative technology adoption. We are excited to work with him and benefit from his valuable insights for the years to come."
「我們很高興保羅加入Pulse Biosciences董事會。他的經歷說明了他幾十年來在醫療技術領域的影響力，」Pulse Biosciences聯合主席羅伯特·W·達根說。「他基於在推動創新技術採用方面成功擴大全球最大心臟病學特許經營權的經驗，給我們的董事會增加了豐富的相關專業知識。我們很高興和他一起工作，並從他寶貴的見解中受益多年。」
Paul LaViolette has significant experience as a large-scale operator at healthcare corporations, as well as an advisor to a diverse group of innovative medical technology startups as a venture investor and board member. He is currently Managing Partner at SV Health Investors, investing in portfolio companies for its Medtech Convergence Fund. Before his investing career, he served in various executive capacities at Boston Scientific Corporation for 15 years, including as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. Prior to Boston Scientific, he also held general management and commercial leadership positions at CR Bard and various marketing roles at Kendall (Medtronic).
保羅·拉維歐萊特在醫療保健公司擔任大規模運營商的經驗豐富，同時也作爲創業投資者和董事會成員爲各種創新醫療技術創業公司提供顧問服務。他目前是SV Health Investors的管理合夥人，爲其Medtech Convergence Fund的投資組合公司投資。在投資生涯之前，他在波士頓科學公司擔任各種高管職務長達15年，包括首席運營官、心血管集團總裁、心臟科總裁、內窺鏡手術集團總裁和國際總裁。在加入波士頓科學公司之前，他還在CR Bard擔任總管理和商業領導職位，以及在Kendall（Medtronic）擔任各種市場營銷職位。
Mr. LaViolette has experience in both chairman and director capacities for numerous private and public medical technology companies. He is currently a director for Edwards Lifesciences, Chairman of the Innovation Advisory Board at Mass General Brigham, and is a director or Chairman on multiple private medical device company boards. Mr. LaViolette received his bachelor's degree in psychology from Fairfield University and his Master of Business Administration from Boston College.
拉維歐萊特先生在許多私營和公共醫療技術公司中擔任主席和董事。他目前是愛德華生命科學公司的董事，麻省總醫院Brigham創新諮詢委員會主席，並在多個私營醫療器械公司董事會上擔任董事或主席。拉維歐萊特先生擁有Fairfield大學心理學學士學位和波士頓學院MBA學位。
"I am honored to join the Board at Pulse Biosciences. The Company's highly differentiated and proprietary technology, and potential to advance the clinical standard of care across numerous therapeutic categories, represents a truly unique opportunity. I am thrilled to be involved with this next-generation energy source and to help the management team methodically develop the most valuable therapeutic treatments to maximize its potential for patients. I am excited to help the team build transformational treatments for unmet patient needs," said Paul LaViolette, incoming Co-Chairman of Pulse Biosciences' Board of Directors.
「我很榮幸加入Pulse Biosciences董事會。該公司高度差異化和專有技術，以及在多個治療領域推進臨床標準的潛力，代表了一個真正獨特的機會。我很高興參與這種下一代能源來源，並幫助管理團隊有條不紊地開發最有價值的治療方案，以最大化其爲患者的潛力。我很興奮能幫助團隊爲未滿足的患者需求打造改變性治療。」保羅·拉維歐萊特，即將擔任Pulse Biosciences董事會聯合主席，說道。
About Pulse Biosciences
關於Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company's proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Florida and maintains its office in Hayward, California.
pulse biosciences是一家新型生物電醫藥公司，致力於健康創新，具有改善患者生活質量的潛力。該公司專有的CellFX nsPFA技術將納秒脈衝電能傳遞到非熱清晰細胞中，同時保護相鄰的非細胞組織。該公司正積極開發其CellFX nsPFA技術，用於治療心房顫動和其他少數市場，在這些市場上，它可能對患者和醫療提供者的醫療保健產生深遠的積極影響。pulse biosciences現總部設在佛羅里達州的邁阿密，並在加利福尼亞州的海沃德維持其辦公室。
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
Pulse Biosciences，CellFX，Nano-Pulse Stimulation，NPS，nsPFA，CellFX nsPFA以及這些圖標都是Pulse Biosciences，Inc.在美國和其他國家/地區的商標和/或註冊商標。
View source version on businesswire.com:
請查看商業線(businesswire.com)的源版本。
Investors:
Pulse Biosciences, Inc.
Burke T. Barrett, President and CEO
IR@pulsebiosciences.com
投資者：
脈衝生物科學公司
巴克·T·巴雷特總裁兼首席執行官
IR@pulsebiosciences.com
Or
或者
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
吉爾馬汀集團
菲利普·特里普·泰勒
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
來源：Pulse Biosciences, Inc.
譯文內容由第三人軟體翻譯。